Search Results
Feb 25, 2026, 09:47 ET As Rare Disease Drug Approvals Accelerate, PANTHERx® Releases Research on Strengthening Care Coordination
Pharmacy to increase awareness of patient challenges for Rare Disease Day (February 28, 2026). About PANTHERx Rare PANTHERx Rare makes rare disease care more hyper-personalized and less overwhelming by focusing relentlessly on each patient and each therapy. PANTHERx experts develop
More news about: PANTHERx Rare Pharmacy
Feb 25, 2026, 09:40 ET Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
tolerability, and preliminary efficacy of a single administration of MZ‑1866 in participants with genetically confirmed Pitt Hopkins syndrome. This rare condition, affecting approximately 1 in 34,000-41,000 individuals and translating to an estimated 8,000 people living with Pitt Hopkins in the Unites
More news about: MAHZI Therapeutics
Feb 25, 2026, 09:35 ET Rowspace launches with $50M to turn institutional knowledge into compounding edge for finance
"They've seen the problem from both sides, pairing technical depth with firsthand understanding of what customers actually need. That combination is rare."Many of Rowspace's backers have been connected to the founders for years before they decided to start the company."We back founders who
More news about: Rowspace
Feb 25, 2026, 09:17 ET VIVICI UNLOCKS ACCESS TO PINK GOLD FOR NUTRITION INNOVATORS
amongst nutrition innovators was that lactoferrin, a whey protein, had vast potential as an ingredient to unlock product innovation, but that it was too rare and expensive to be commercially viable. That changes today, with Dutch ingredients company Vivici launching Vivitein™ LF in the US market.
More news about: Vivici
Feb 25, 2026, 09:15 ET Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
feasible.The researchers are seeking genomic alternative approaches. Existing translational research ctDNA assays can miss disease signals in very rare tumors such as Wilms and rhabdoid. Illumina's 5-base solution enabled simultaneous genomic and methylation profiling to add additional epigenomics signals
More news about: Illumina, Inc.
Feb 25, 2026, 09:00 ET LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION
Time-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab EfficacyRARE INVESTOR ALERT"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi
More news about: Levi & Korsinsky, LLP
Feb 25, 2026, 09:00 ET BENLEE Manufacturing Reports Record 2025 Revenue and Shipments, Positioned to Capitalize on U.S. Administration's Push to Revitalize American Manufacturing
shipments in 2025, with strong momentum heading into 2026 as 50% steel tariffs andsurging demand from AI data centers, semiconductor plants, rare earth materials and defensespending drive scrap metal recycling and domestic energy production ROMULUS,
More news about: BENLEE INC.
Feb 25, 2026, 09:00 ET RealityMine® Appoints Former Google Executive Phil Miles to Chairman of the Board Following Strong US Growth
has agreed to chair the RealityMine board," said Chris Havemann, CEO of RealityMine. "Having spent nearly 20 years at Google and YouTube, he brings a rare, insider's understanding of how the world's leading technology companies think, scale, and compete. As we look ahead to the next three to five years,
More news about: RealityMine
Feb 25, 2026, 09:00 ET Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
FDA in mid-April to align on study design, and believes a clinical trial of well under 100 subjects will be sufficient to secure approval in this rare cancer indication.With sufficient cash on hand to execute near-term milestones, the company expects to avoid immediate material dilution, redirecting
More news about: Equity Insider
Feb 25, 2026, 08:51 ET AlarMax Appoints Steve Teitelbaum as Chief Technology Officer, Uniting Industry Legacy with AI-Driven Innovation
directly to President Scott Shelander and work closely with executive leadership to align technology investments with business strategy."Steve is a rare leader who combines deep technical mastery with a genuine understanding of our industry and our culture," said Scott Shelander, President of AlarMax.
More news about: AlarMax Distributors, Inc.
Feb 25, 2026, 08:41 ET One Night Out with Alan Cumming Coming to Crave and CTV Comedy Channel in Canada Thursday, February 26
Griffin, Executive Producer and VP, Television & Creative Strategy at Just For Laughs. "The special is electric — joyful, fearless, and one of those rare comedy events that feels bigger than the moment."With Cumming — Emmy-winning host of The Traitors US — at the helm, the special
More news about: Just For Laughs
Feb 25, 2026, 08:30 ET Pharma is Losing $250 Billion to Patient Dropout. Here's How to Stop It.
Recruitment & Retention | Medical Education & Field Force AmplificationTherapy areas: Oncology, Auto-Immune, Neurology, Rare & Ultra Rare Disease and complex MedTech.Ian Read Joins as Strategic AdvisorIan Read served as Pfizer's CEO (2010–2018) overseeing transformative
More news about: Hoot Health, Inc.
Feb 25, 2026, 08:30 ET Sunderstorm Accelerates Global Growth for Its KANHA Brand With Strategic Partnerships to Scale Medical-Grade Cannabis Products Across Europe and Australia
FuGu HoldingsRooted deeply in the culture and legacy of cannabis, FuGu Holdings is redefining the Australian cannabis market with a focus on rare and exclusive cultivars from artisan growers around the world. Founded in 2024, FuGu Holdings has quickly become one of the leading companies domestically,
More news about: Sunderstorm
Feb 25, 2026, 08:07 ET P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments
capabilities in genomic patient identification, and enhancing the development of and access to advanced therapies in a region disproportionately affected by rare diseases. The partnership positions P4ML at the center of the rapidly expanding $25B+ global Advanced Therapy Medicinal Products (ATMP) market,
More news about: Orphan Therapeutics Accelerator
Feb 25, 2026, 08:00 ET SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDMTM, a platform that analyzes complex genomic and multimodal data and generates
More news about: SOPHiA GENETICS
Feb 25, 2026, 07:18 ET Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
this significant milestone for imsidolimab's acceptance for review by the FDA during Rare Disease Week on Capitol Hill (February 24–26, 2026), as advocates unite to promote innovation and access to treatments for rare orphan diseases like generalized pustular psoriasis.If imsidolimab is approved,
More news about: Vanda Pharmaceuticals Inc.
Feb 25, 2026, 07:15 ET Ontario court orders unprecedented $80,000 costs award against Ontario Securities Commission in MyForexFunds case
The decision follows a major ruling that ordered the return of the vast majority of business assets that had been frozen since August 2023.In a rare and pointed critique of the regulator, Justice Kimmel stated in her reasons: "the court has not been overly impressed with the manner in which the Commission
More news about: MyForexFunds
Feb 25, 2026, 07:05 ET REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for
More news about: REGENXBIO Inc.
Feb 25, 2026, 07:00 ET CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia®. Cumberland has assumed responsibility for the
More news about: Cumberland Pharmaceuticals Inc.
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
the discovery and initial characterization of ATX-01 (formerly known as X82108), ARTHEx's lead therapeutic candidate in clinical testing for DM1, a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. ATX-01 is an anti-miR oligonucleotide designed to inhibit microRNA23b (miR-23b), which
More news about: ARTHEx Biotech
Feb 25, 2026, 00:02 ET Children's Hospital of Philadelphia Marks One-Year Anniversary of World's First Personalized CRISPR Gene Therapy for Child with Rare Genetic Disease
collaboration with the Rare Disease Congressional Caucus and the Personalized Medicine Caucus, highlighting the need for sustained federal funding for pediatric research and policies that expand access to personalized gene therapies."As KJ's parents, we want to put a human face on rare diseases," said
More news about: Children's Hospital of Philadelphia
Feb 24, 2026, 20:57 ET Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 24, 2026, 18:52 ET QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm
N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 24, 2026, 17:54 ET Charles Zhang and Lynn Chen-Zhang Named Recipients of the 2026 Ellis Island Medal of Honor
principles, the honor is awarded solely on the basis of individual merit and societal contribution. It is not conferred jointly. While there have been rare instances in which spouses have each been recognized, such cases remain exceptional and reflect independent accomplishments and impact.Mr. Zhang
More news about: Zhang Financial
Feb 24, 2026, 16:23 ET Jonathan De Armas From De Armas Law Named "Attorney of the Year" by Orlando Style Magazine
jury trial. He later moved into civil practice, joining one of Florida's largest insurance defense firms and then a plaintiff's practice, gaining a rare dual perspective on how insurers evaluate, defend, and resolve claims.Founding De Armas Law: In 2019, Jonathan De Armas opened his own
More news about: De Armas Law Firm